Precision proteogenomics reveals pan-cancer impact of germline variants
- PMID: 40233739
- PMCID: PMC12326532
- DOI: 10.1016/j.cell.2025.03.026
Precision proteogenomics reveals pan-cancer impact of germline variants
Abstract
We investigate the impact of germline variants on cancer patients' proteomes, encompassing 1,064 individuals across 10 cancer types. We introduced an approach, "precision peptidomics," mapping 337,469 coding germline variants onto peptides from patients' mass spectrometry data, revealing their potential impact on post-translational modifications, protein stability, allele-specific expression, and protein structure by leveraging the relevant protein databases. We identified rare pathogenic and common germline variants in cancer genes potentially affecting proteomic features, including variants altering protein abundance and structure and variants in kinases (ERBB2 and MAP2K2) impacting phosphorylation. Precision peptidome analysis predicted destabilizing events in signal-regulatory protein alpha (SIRPA) and glial fibrillary acid protein (GFAP), relevant to immunomodulation and glioblastoma diagnostics, respectively. Genome-wide association studies identified quantitative trait loci for gene expression and protein levels, spanning millions of SNPs and thousands of proteins. Polygenic risk scores correlated with distal effects from risk variants. Our findings emphasize the contribution of germline genetics to cancer heterogeneity and high-throughput precision peptidomics.
Keywords: CPTAC; germline; pan-cancer; precision peptidomics; proteogenomics.
Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no competing interests.
References
-
- Villani A, Tabori U, Schiffman J, Shlien A, Beyene J, Druker H, Novokmet A, Finlay J, and Malkin D. (2011). Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol. 12, 559–567. 10.1016/S1470-2045(11)70119-X. - DOI - PubMed
MeSH terms
Substances
Grants and funding
- U24 CA210954/CA/NCI NIH HHS/United States
- U01 CA214116/CA/NCI NIH HHS/United States
- U24 CA210985/CA/NCI NIH HHS/United States
- U24 CA210967/CA/NCI NIH HHS/United States
- U24 CA210986/CA/NCI NIH HHS/United States
- HHSN261201500003C/CA/NCI NIH HHS/United States
- U24 CA270823/CA/NCI NIH HHS/United States
- U24 CA210972/CA/NCI NIH HHS/United States
- U24 CA210955/CA/NCI NIH HHS/United States
- R35 CA197588/CA/NCI NIH HHS/United States
- U24 CA210993/CA/NCI NIH HHS/United States
- U24 CA211006/CA/NCI NIH HHS/United States
- R01 HG009711/HG/NHGRI NIH HHS/United States
- R33 CA263705/CA/NCI NIH HHS/United States
- R35 CA253183/CA/NCI NIH HHS/United States
- S10 OD030463/OD/NIH HHS/United States
- HHSN261201500003I/CA/NCI NIH HHS/United States
- U24 CA210979/CA/NCI NIH HHS/United States
- U24 CA271012/CA/NCI NIH HHS/United States
- U01 CA214114/CA/NCI NIH HHS/United States
- U01 CA214125/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous